Treatment of Recurrent GBM With APG-157 Via Expanded Access

Glioblastoma Clinical Trial

Official title:

Treatment of Recurrent GBM With APG-157 Via Expanded Access

Clinical Trial Details — Status: Available

Administrative data

• NCT number: NCT05551013
• Other study ID #: BSW AVTA
• Status: Available

Study information

• Verified date: January 2024
• Source: Aveta Biomics, Inc.
• Contact: Dedra L Preece, BS
• Phone: 254-724-5939
• Email: dedra.preece[@]bswhealth.org
• Is FDA regulated: No
• Study type: Expanded Access

Clinical Trial Summary

This expanded access request will evaluate APG-157, a botanical drug under development for other cancers, as potential treatment for recurrent Glioblastoma multiforme (GBM) patients.

Description:

Glioblastoma patients with disease recurrence after primary, currently approved primary treatments have limited options. Therefore, this expanded access trial is designed to test a new therapeutic option for these patients.

Patients who have progressed on a combination of both Temozolomide and Tumor Treating Field (Optune) or as single treatment Temozolomide (TMZ) OR Tumor Treating Fields (Optune) are eligible to receive APG-157. During APG-157 dosing, TMZ or Optune may be concurrently given at the decision of the Principal Investigator. APG-157 will be given until disease progression or intolerance by the patient.

Radiation followed by adjuvant Temozolomide for 6 to 12 months which is a current standard of care (SOC). Upon progression of this disease after SOC treatment, there are very limited further options for these patients. This expanded access administration will evaluate the potential of APG-157, a novel drug under development for head and neck cancer, as a potential treatment for these recurrent glioblastoma patients.

Brief Description of Objectives:

• Improve six-month progression-free survival (PFS) and overall survival (OS) of the patients eligible for the treatment under Expanded Access protocol.

• Improvement in Quality of Life

• Achievements of above two objectives without any Serious Adverse Events (SAEs) and adverse drug-drug interactions.

Brief Description of Plans for Efficacy Assessment:

• Improvement in Quality of Life

• Efficacy will be assessed using Imaging (objective tumor response using Response Assessment in Neuro-Oncology criteria (RANO), hematological assessment, and tolerance.

Recruitment information / eligibility

• Status: Available
• Enrollment: 0
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• This study will enroll patients with histologically confirmed glioblastoma (GBM).

• Patients must have received prior treatment with standard first-line therapy for GBM, including maximal surgical resection and postoperative external-beam radiotherapy or Tumor Treating Fields (Optune). Concurrent chemoradiation with TMZ or Tumor Treating Field (Optune) is allowed but not mandatory.

• Patients are eligible for enrollment only if they have unequivocal evidence of tumor recurrence/progression by MRI a minimum of 12 weeks following completion of radiation therapy or TMZ-Radiotherapy or Optune. Patients who have received prior bevacizumab or other anti-vascular endothelial growth factor(anti-VEGF) agents are not eligible to enroll.

• Baseline MRI should be performed within 28 days prior to enrollment.

• Other key inclusion criteria include Eastern Cooperative Oncology Group (ECOG) status of 0-1 (KPS = 70%) and adequate bone marrow, hepatic, and renal function at baseline.

Exclusion Criteria:

• Patients with severe neutropenia

Related Conditions & MeSH terms

• Glioblastoma
• Glioblastoma Multiforme

Intervention

Drug:
• APG-157
APG-157 is an orally administered drug encased in a hydrogel pastille. Arms: Ongoing Stupp protocol (will receive concurrent TMZ + APG-157) Progression post TMZ (will receive APG-157 only) Ongoing Optune (will receive concurrent Optune + APG-157) Progression post Optune (will receive APG-157 only)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Aveta Biomics, Inc.